This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
A single therapy may be able to treat inherited disorders of both the kidneys and eyes—and potentially more genetic diseases called proteinopathies, researchers at the Broad Institute have discovered.
The diseases are all caused by mutated proteins that don't fold correctly and end up accumulating, eventually killing cells. The new therapeutic approach unclogs the traffic jam of misfolded proteins by targeting an entrapment complex, a malfunctioning arm of the cell's trafficking machinery.
In 2019, the same team of researchers reported the role of one protein in the cell, TMED9, in causing accumulation of misfolded proteins in a rare disease called MUC1 kidney disease. Now, they've shown that TMED9 is part of a larger complex that includes four proteins—TMED2, 7, 9 and 10—and that a small molecule they developed to target this machine works in mice against both MUC1 kidney disease and the rare genetic eye disorder retinitis pigmentosa.
"We've identified a shared mechanism behind many seemingly disparate diseases that, on their own, are each quite rare and don't drive a lot of investment for therapeutic development," said Anna Greka, a core institute member of the Broad and senior author of the new paper. "But put all these conditions together, and a drug treating all of them is suddenly something that could benefit millions of patients."
Greka adds that the new study is evidence of "nodal biology"—where different diseases share common biological "nodes" or mechanisms that can be targeted by the same drug.
Source link







